Sort   by:  
 Page size 
UnknownStructure-guided design and characterization of a clickable, covalent PARP16 inhibitor.
Not available
S-EPMC9710212 | biostudies-literature
UnknownSMYD3-PARP16 axis accelerates unfolded protein response and mediates neointima formation.
Not available
S-EPMC8148056 | biostudies-literature
UnknownSmyd3-PARP16 axis accelerates unfolded protein response and vascular aging.
Not available
S-EPMC7695420 | biostudies-literature
UnknownPARP16-Mediated Stabilization of Amyloid Precursor Protein mRNA Exacerbates Alzheimer's Disease Pathogenesis.
Not available
S-EPMC10389827 | biostudies-literature
UnknownEpigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity.
Not available
S-EPMC5502302 | biostudies-literature
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Phosphoproteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020484 | Pride
Adavosertib Phosphoproteomics Parp16 Lung cancer Parp1 Polypharmacology Parp inhibitor Ewing’s sarcoma Off-target Talazoparib 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Chemical Proteomics Cal51
PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, o...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020520 | Pride
Adavosertib Parp16 Breast cancer Parp1 Polypharmacology Parp inhibitor Proteomics Off-target Talazoparib 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Chemical Proteomics
PARP1 inhibitors (PARP1is) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, o...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020455 | Pride
Adavosertib Parp16 Lung cancer Parp1 Polypharmacology Parp inhibitor Ewing’s sarcoma Proteomics Off-target Talazoparib 
ProteomicsThe non-canonical PARP1 inhibitor target, PARP16, contributes to talazoparib polypharmacology and synergy with WEE1 inhibitors: Expression Proteomics
PARP1 inhibitors (PARP1is ) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2 mutations. Here, we determined the differential efficacy of multiple clinical PARP1is in SCLC cells. Compared to the other PARP1is (rucaparib, ...
ORGANISM(S): Homo sapiens (Human) 
2021-07-21 | PXD020485 | Pride
Adavosertib Parp16 Parp1 Small cell lung cancer Polypharmacology Parp inhibitor Proteomics Off-target Talazoparib 
UnknownThe non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Not available
S-EPMC8782927 | biostudies-literature
Sort   by:  
 Page size